The life science industry has been in transition for more than a decade. With the shift away from the traditional set-up, where a dozen established players each claimed their own piece of the pie, life sciences companies are now having to reinvent themselves to adapt to a new business context. And that requires – even more so than in other industries – a quest for a continuous balance between patient-centricity and bottom-line business results.
Challenges for the life science industry
With an industry-wide move from treatment to prevention, informed and demanding patients become partners in their own health care. New business models revolve around end-to-end transparency and integrity.
Mergers & acquisitions
Newly formed organizations require a new equilibrium in terms of people, processes, technology and responsibilities. The quest for performance improvement is ongoing.
Moving into the digital era challenges everyone in the industry to rethink their current operating model. Whether it is in planning, production, distribution or customer service, transformation will be the new key success factor.
“End-to-End visibility is the new holy grail to become responsive to changes in global demand.”
We design across strategic, tactical and operational supply chain levels to optimize your end-to-end network. At the heart of compliance are serialization and track & trace, for which we have a proven track record not only in life sciences but also in food & beverages.
Digitization and big data allow you to shine when it comes to transparency and bottom line results. By embracing industry 4.0 techniques, we have developed a state-of-the-art planning tool: LightsOutPlanning.
Balance supply and demand in a realistic way. Binocs is our best-of-breed web application to ensure you have qualified/skilled people in R&D, quality operations and engineering to deliver planned project and day-to-day work on time.
GlaxoSmithKline (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare.
Abbott creates breakthrough products in diagnostics, medical devices, nutrition and branded generic pharmaceuticals. For more than 125 years, it has been making a lasting impact on health in more than 150 different countries.
Pfizer is among the world’s largest pharmaceutical companies. It develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology and neurology.
Baxter touches millions of lives every day. Their products and services are essential building blocks of today’s healthcare. You find Baxter products and therapies in almost every hospital worldwide, on every floor and in every department as well as in many individual people’s homes.
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. The company focuses on treatments for severe diseases, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Ablynx is a Belgian biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders.
Bilthoven Biologicals is a bioengineering and pharmaceutical company. It develops and produces vaccines and offers contract manufacturing services.
Improved Agility is Key for Your Supply-Chain Excellence
An agile supply chain must be responsive to actual demand, and capable of using information as a substitute (to some degree) for inventory through collaboration and integration with key customers and suppliers.
Industry 4.0: Trends That Will Reshape the Way Things Are Made? Or Just a Flashy Catchphrase?
Will the powerful emerging currents, such as big data, advanced analytics, human–machine interfaces and digital-to-physical transfer, reach their unmistakably high potential and cause a fourth major upheaval in modern manufacturing? According to Cornelius Baur (director at McKinsey Munich) and Dominic Wee (partner at McKinsey Munich)...
The Four Heart Attacks Your Supply Chain Lead Should Survive When Facing Anti-Counterfeit Regulations
With the emergence throughout the last decades of thefts, counterfeit medicines and parallel trades within the pharmaceutical sector, the publication of anti-counterfeit regulations throughout countries/regions has been well received within the healthcare sector.
Last April, bluecrux attented LogiPharma, the largest global event bringing together supply chain professionals from top pharma companies. To be honest, we were amazed by the open, honest and constructive atmosphere that ran through all the sessions. In the light of that openness, we, on...